Viewing data from:

ENFLONSIA

BLA

CLESROVIMAB-CFOR | B761432 | MERCK SHARP DOHME

1 product0 Purple Book patents

Biologic LOEProtected

Estimated date when biosimilar competition may begin

June 9, 2037(3994 days remaining)

Regulatory Exclusivities

Type	Expiry	Status	Source
12-Year BPCIA	Jun. 9, 2037	Active	Computed

Purple Book Patents

No listed patents in Purple Book.

Estimated Patent LOE

Jun. 26, 20456933 days remaining

Based on latest discovered patent 12344670 · relevance 80/100

Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.

Discovered Patents

View all 208 patents →

Top 50 of 208 AI-discovered patents by relevance.

Composition

(29)

85/1008557232Grant: 2013-10-15 | Exp: 2033-10-10

85/1007824897Grant: 2010-11-02 | Exp: 2030-10-28

85/1006531290Grant: 2003-03-11 | Exp: 2023-03-06

85/1006258944Grant: 2001-07-10 | Exp: 2021-07-05

85/1007579440Grant: 2009-08-25 | Exp: 2029-08-20

85/1007615615Grant: 2009-11-10 | Exp: 2029-11-05

82/10010227392Grant: 2019-03-12 | Exp: 2039-03-07

82/1009328170Grant: 2016-05-03 | Exp: 2036-04-28

82/1007510853Grant: 2009-03-31 | Exp: 2029-03-26

82/10011292848Grant: 2022-04-05 | Exp: 2042-03-31

82/1008007809Grant: 2011-08-30 | Exp: 2031-08-25

82/1007411041Grant: 2008-08-12 | Exp: 2028-08-07

78/10010093707Grant: 2018-10-09 | Exp: 2038-10-04

78/1007976848Grant: 2011-07-12 | Exp: 2031-07-07

78/1007541439Grant: 2009-06-02 | Exp: 2029-05-28

78/1006512103Grant: 2003-01-28 | Exp: 2023-01-23

75/1007049296Grant: 2006-05-23 | Exp: 2026-05-18

75/1008361957Grant: 2013-01-29 | Exp: 2033-01-24

75/1008344114Grant: 2013-01-01 | Exp: 2032-12-27

75/1008093010Grant: 2012-01-10 | Exp: 2032-01-05

75/10012343378Grant: 2025-07-01 | Exp: 2045-06-26

75/10010196434Grant: 2019-02-05 | Exp: 2039-01-31

75/10012145970Grant: 2024-11-19 | Exp: 2044-11-14

75/1008470979Grant: 2013-06-25 | Exp: 2033-06-20

75/1006933134Grant: 2005-08-23 | Exp: 2025-08-18

75/1007138264Grant: 2006-11-21 | Exp: 2026-11-16

75/1008372402Grant: 2013-02-12 | Exp: 2033-02-07

75/1008420093Grant: 2013-04-16 | Exp: 2033-04-11

75/10012042524Grant: 2024-07-23 | Exp: 2044-07-18

Formulation

(2)

85/10011406706Grant: 2022-08-09 | Exp: 2042-08-04

85/10010772947Grant: 2020-09-15 | Exp: 2040-09-10

Method of Use

(3)

78/1007740848Grant: 2010-06-22 | Exp: 2030-06-17

75/1008067472Grant: 2011-11-29 | Exp: 2031-11-24

75/1008178488Grant: 2012-05-15 | Exp: 2032-05-10

Manufacturing

(6)

88/10010369213Grant: 2019-08-06 | Exp: 2039-08-01

75/1007326567Grant: 2008-02-05 | Exp: 2028-01-31

75/1008062886Grant: 2011-11-22 | Exp: 2031-11-17

75/1008445227Grant: 2013-05-21 | Exp: 2033-05-16

75/1006436402Grant: 2002-08-20 | Exp: 2022-08-15

75/1007744892Grant: 2010-06-29 | Exp: 2030-06-24

other

(10)

90/10011884724Grant: 2024-01-30 | Exp: 2044-01-25

85/10011001640Grant: 2021-05-11 | Exp: 2041-05-06

85/10010759856Grant: 2020-09-01 | Exp: 2040-08-27

85/10011959118Grant: 2024-04-16 | Exp: 2044-04-11

85/10010640559Grant: 2020-05-05 | Exp: 2040-04-30

82/1009624298Grant: 2017-04-18 | Exp: 2037-04-13

80/10012344670Grant: 2025-07-01 | Exp: 2045-06-26

78/1009701751Grant: 2017-07-11 | Exp: 2037-07-06

75/10010487147Grant: 2019-11-26 | Exp: 2039-11-21

75/10010982008Grant: 2021-04-20 | Exp: 2041-04-15

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 761432

351(a) ReferenceLicensedCDERInjection

Proper Name

clesrovimab-cfor

Applicant

Merck Sharp & Dohme LLC

Approval Date

9-Jun-25

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jun 10, 2025	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 105MG/0.7ML

▴

INJECTION;SOLUTION | Approved: 2025-06-09 00:00:00

No patent or exclusivity listings for this strength.